MX2014008283A - Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. - Google Patents
Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.Info
- Publication number
- MX2014008283A MX2014008283A MX2014008283A MX2014008283A MX2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A
- Authority
- MX
- Mexico
- Prior art keywords
- extended
- urination
- frequency
- reducing
- release formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Power-Operated Mechanisms For Wings (AREA)
- Guiding Agricultural Machines (AREA)
Abstract
Se describen métodos y composiciones para reducir la frecuencia para orinar. Un método comprende administrar a un sujeto en necesidad de ésta, una cantidad efectiva de una composición farmacéutica que comprende un agente analgésico formulado en una formulación de liberación prolongada. Otro método comprende administrar a un sujeto en necesidad de ésta, una cantidad efectiva de una composición farmacéutica que comprende múltiples ingredientes activos formulados para liberación prolongada. Aún otro método comprende administrar a un sujeto en necesidad de ésta una cantidad efectiva de un diurético, seguido con otra administración de una composición farmacéutica que comprende un agente analgésico formulado para liberación prolongada.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/343,332 US20120135050A1 (en) | 2010-07-08 | 2012-01-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US13/424,000 US8236857B2 (en) | 2010-07-08 | 2012-03-19 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US13/487,348 US20120244221A1 (en) | 2010-07-08 | 2012-06-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
PCT/US2012/051888 WO2013103390A1 (en) | 2012-01-04 | 2012-08-22 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014008283A true MX2014008283A (es) | 2015-03-03 |
Family
ID=48745355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008283A MX2014008283A (es) | 2012-01-04 | 2012-08-22 | Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. |
Country Status (13)
Country | Link |
---|---|
US (3) | US8685453B2 (es) |
JP (4) | JP2015503583A (es) |
KR (2) | KR20140108675A (es) |
AU (2) | AU2012363789B2 (es) |
BR (1) | BR112014016661A8 (es) |
CA (1) | CA2856677A1 (es) |
IL (1) | IL232715A0 (es) |
MX (1) | MX2014008283A (es) |
MY (1) | MY173582A (es) |
RU (1) | RU2603471C2 (es) |
SG (1) | SG11201500407XA (es) |
WO (1) | WO2013103390A1 (es) |
ZA (1) | ZA201404606B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
CN103796669B (zh) | 2011-07-18 | 2016-11-09 | 重症监护诊断股份有限公司 | 治疗心血管疾病和预测运动疗法功效的方法 |
CN104219964B (zh) * | 2012-03-30 | 2016-09-21 | 奇华顿股份有限公司 | 作为食品加香化合物的n-酰基脯氨酸衍生物 |
KR20170010440A (ko) * | 2014-06-06 | 2017-01-31 | 웰즐리 파마슈티컬스 엘엘씨 | 배뇨 빈도를 감소시키기 위한 약학적 제형 및 이의 사용방법 |
RU2017113827A (ru) * | 2014-09-24 | 2018-10-24 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения |
RU2018111400A (ru) * | 2015-09-01 | 2019-10-03 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Препарат пролонгированного, отсроченного и немедленного высвобождения, способ его получения и применения |
RU2018111401A (ru) * | 2015-09-01 | 2019-10-02 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Составы с отсроченным высвобождением, способы их получения и применения |
EP3355877A4 (en) * | 2015-09-30 | 2019-05-15 | Wellesley Pharmaceuticals, LLC | COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF |
TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
JP7229012B2 (ja) * | 2018-12-25 | 2023-02-27 | 小林製薬株式会社 | 内服用医薬組成物 |
JP2019069991A (ja) * | 2018-12-27 | 2019-05-09 | ウェルズリー ファーマスーティカルズ、エルエルシー | 膀胱痙攣を低減するための医薬製剤およびその使用の方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU651247B2 (en) * | 1991-09-06 | 1994-07-14 | Mcneilab, Inc. | Composition comprising a tramadol material and acetaminophen and its use |
AU6747698A (en) * | 1997-04-11 | 1998-11-11 | Nippon Shinyaku Co. Ltd. | Remedies for frequent urination and urinary incontinence |
US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
JP3660979B2 (ja) * | 2000-09-05 | 2005-06-15 | 国立大学法人金沢大学 | 夜間頻尿症の治療剤、夜間頻尿症の予防剤 |
RU2193401C1 (ru) * | 2001-04-02 | 2002-11-27 | Аль-Шукри Салман Хасунович | Способ лечения гиперактивности мочевого пузыря |
WO2003043655A1 (fr) * | 2001-11-19 | 2003-05-30 | Ono Pharmaceutical Co., Ltd. | Remedes pour la frequence urinaire |
PL372395A1 (en) * | 2002-02-19 | 2005-07-25 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
AU2003281044A1 (en) * | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Pyrrolopyridine derivative and use thereof |
KR100522239B1 (ko) * | 2002-07-16 | 2005-10-18 | 주식회사 서울제약 | 아세트아미노펜을 함유하는 제어방출성의 경구용 제제 |
US20050152905A1 (en) * | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
EP1555022B1 (en) * | 2002-09-21 | 2008-02-20 | Shuyi Zhang | Sustained release formulation of acetaminophen and tramadol |
US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
ATE345120T1 (de) * | 2003-03-21 | 2006-12-15 | Dynogen Pharmaceuticals Inc | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
US8029822B2 (en) | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
DE10356112A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
JP2008511611A (ja) * | 2004-08-30 | 2008-04-17 | ルナメツド・インコーポレーテツド | 治療用4−フェニル酪酸制御放出製剤 |
US20080009538A1 (en) * | 2005-03-21 | 2008-01-10 | Phil Skolnick | Methods and compositions for the treatment of urinary incontinence |
WO2006105670A1 (en) * | 2005-04-08 | 2006-10-12 | Neuromed Pharmaceuticals Ltd. | Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
US20100204333A1 (en) * | 2005-07-20 | 2010-08-12 | Panacea Biotec Ltd. | Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor |
US20080166407A1 (en) | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
WO2007072503A2 (en) * | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
US20070237816A1 (en) * | 2006-04-06 | 2007-10-11 | David Finkelstein | Acetaminophen formulation for joint pain relief |
US20090252787A1 (en) | 2006-07-28 | 2009-10-08 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
PL2190418T3 (pl) * | 2007-08-15 | 2014-03-31 | Mcneil Ppc Inc | Sposób dawkowania ibuprofenu o natychmiastowym i długotrwałym uwalnianiu |
GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
-
2012
- 2012-08-22 RU RU2014131285/15A patent/RU2603471C2/ru not_active IP Right Cessation
- 2012-08-22 MY MYPI2014701369A patent/MY173582A/en unknown
- 2012-08-22 AU AU2012363789A patent/AU2012363789B2/en not_active Ceased
- 2012-08-22 SG SG11201500407XA patent/SG11201500407XA/en unknown
- 2012-08-22 KR KR1020147018677A patent/KR20140108675A/ko active Application Filing
- 2012-08-22 BR BR112014016661A patent/BR112014016661A8/pt not_active Application Discontinuation
- 2012-08-22 CA CA2856677A patent/CA2856677A1/en not_active Abandoned
- 2012-08-22 WO PCT/US2012/051888 patent/WO2013103390A1/en active Application Filing
- 2012-08-22 KR KR1020187005757A patent/KR20180025993A/ko active IP Right Grant
- 2012-08-22 JP JP2014551234A patent/JP2015503583A/ja active Pending
- 2012-08-22 MX MX2014008283A patent/MX2014008283A/es unknown
-
2013
- 2013-03-20 US US13/847,927 patent/US8685453B2/en not_active Expired - Fee Related
-
2014
- 2014-02-04 US US14/172,649 patent/US20140154320A1/en not_active Abandoned
- 2014-05-20 IL IL232715A patent/IL232715A0/en unknown
- 2014-06-23 ZA ZA2014/04606A patent/ZA201404606B/en unknown
-
2015
- 2015-06-04 US US14/730,934 patent/US20150272968A1/en not_active Abandoned
-
2016
- 2016-09-13 JP JP2016178118A patent/JP2017031172A/ja active Pending
-
2017
- 2017-05-22 AU AU2017203418A patent/AU2017203418B2/en not_active Ceased
-
2018
- 2018-02-02 JP JP2018016869A patent/JP2018087217A/ja active Pending
-
2019
- 2019-11-08 JP JP2019203550A patent/JP2020037575A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20130216620A1 (en) | 2013-08-22 |
RU2603471C2 (ru) | 2016-11-27 |
ZA201404606B (en) | 2015-11-25 |
AU2012363789A1 (en) | 2014-07-17 |
JP2017031172A (ja) | 2017-02-09 |
NZ626619A (en) | 2017-03-31 |
IL232715A0 (en) | 2014-07-31 |
JP2018087217A (ja) | 2018-06-07 |
JP2020037575A (ja) | 2020-03-12 |
JP2015503583A (ja) | 2015-02-02 |
RU2014131285A (ru) | 2016-02-20 |
AU2012363789A2 (en) | 2014-07-24 |
AU2017203418A1 (en) | 2017-06-08 |
SG11201500407XA (en) | 2015-03-30 |
BR112014016661A2 (pt) | 2017-06-13 |
BR112014016661A8 (pt) | 2017-07-04 |
US20140154320A1 (en) | 2014-06-05 |
CA2856677A1 (en) | 2013-07-11 |
MY173582A (en) | 2020-02-04 |
US20150272968A1 (en) | 2015-10-01 |
NZ732149A (en) | 2018-11-30 |
US8685453B2 (en) | 2014-04-01 |
NZ721818A (en) | 2017-07-28 |
AU2017203418B2 (en) | 2019-01-17 |
KR20140108675A (ko) | 2014-09-12 |
AU2012363789B2 (en) | 2017-04-13 |
WO2013103390A1 (en) | 2013-07-11 |
KR20180025993A (ko) | 2018-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014008284A (es) | Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta. | |
MX2014008283A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. | |
MY174090A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
MX2019003467A (es) | Formulaciones y metodos para la administracion vaginal de antiprogestinas. | |
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
WO2012145575A3 (en) | Therapy for leukemia | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
MX2016016039A (es) | Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización.. | |
IN2014DN10134A (es) | ||
MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
ECSP12012332A (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
PH12015500070B1 (en) | Pediatric oral liquid compositions containing nepadutant | |
CO6630144A2 (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
IN2013MU02111A (es) | ||
UA60688U (ru) | Фармацевтическая композиция для лечения заболеваний органов дыхания и заболеваний аллергического типа | |
IN2013MU02110A (es) | ||
AR063816A1 (es) | Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion |